NASDAQ: EVOEvotec Se Stock
$11.67+0.49 (+4.38%)
Updated Jun 2, 2023
EVO Price
$11.67
Fair Value Price
N/A
Market Cap
$4.13B
52 Week Low
$7.80
52 Week High
$11.67
P/E
-21.45x
P/B
3.17x
P/S
3.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$825.77M
Earnings
-$186.87M
Gross Margin
23.2%
Operating Margin
-18.74%
Profit Margin
-23.4%
Debt to Equity
0.9
Operating Cash Flow
$216M
Beta
1.35
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EVO Overview
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EVO is poor value based on its book value relative to its share price (3.17x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.79x)
P/B vs Industry Valuation
EVO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EVO due diligence checks available for Premium users.
Be the first to know about important EVO news, forecast changes, insider trades & much more!
EVO News
Valuation
EVO fair value
Fair Value of EVO stock based on Discounted Cash Flow (DCF)
Price
$11.67
Fair Value
$10.52
Overvalued by
10.96%
EVO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-21.45x
Industry
14.9x
Market
52.69x
EVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.17x
Industry
1.79x
EVO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EVO's financial health
Profit margin
Revenue
$256.1M
Net Income
-$28.9M
Profit Margin
-11.3%
EVO's Earnings (EBIT) of -$154.73M... subscribe to Premium to read more.
Interest Coverage Financials
EVO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.4B
Liabilities
$1.1B
Debt to equity
0.9
EVO's short-term assets ($1.18B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVO's short-term assets ($1.18B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$35.7M
Investing
$20.4M
Financing
-$2.1M
EVO's operating cash flow ($223.19M)... subscribe to Premium to read more.
Debt Coverage Financials
EVO vs Pharmaceutical Stocks
Evotec Se Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.